SecBot SecBot
144 ·Filed Aug 14, 2026

CCCC

C4 Therapeutics, Inc.
NEUTRAL
Impact 3/10
Horizondays Processed3mo ago SEC0001950047-26-008190
Form 144, notice of proposed sale of securities
Actionable Insight • Neutral

The Form 144 signals intent to sell a modest position relative to market cap. Monitor for actual Form 4 filings to confirm execution and watch for any additional insider sales or changes in company guidance that might explain the timing.

DirectionNeutral
Confidencemedium
Horizondays

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$4.27
T+0 close · Aug 14, 2026 · via day close
Latest settled
−26.14%
T+60 · $3.15
Vs SPY
−23.38%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Aug 17 $4.27entry
  2. T+1 · 3mo ago −1.99%α −1.32% · $4.18
  3. T+5 · 3mo ago −3.87%α −2.68% · $4.10
  4. T+20 · 2mo ago −19.58%α −18.05% · $3.43
  5. T+60 · 7d ago −26.14%α −23.38% · $3.15
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Jay L. Geldmacher, a former REZI CEO and reporting owner of C4 Therapeutics, filed a Form 144 notice of intent to sell approximately 82,563 shares of common stock with an estimated aggregate market value of ~$1.9 million. The shares were acquired through restricted stock and performance share grants between 2024 and 2025. This is a relatively small sale relative to C4's $502M market cap, but the insider's role and the timing (no specific catalyst noted) warrant monitoring for potential follow-through sales or insider sentiment shifts.

Key Facts

  • Jay L. Geldmacher filed Form 144 to sell up to 82,563 shares of C4 Therapeutics common stock.
  • Estimated aggregate market value of the proposed sale is approximately $1,899,926.
  • Shares were acquired via restricted stock and performance share grants dated 02/09/2025, 02/14/2025, 02/15/2025, 02/18/2024, and 02/14/2024.
  • The filing date is August 14, 2026, with the proposed sale date also listed as August 14, 2026.
  • The sale is planned through Morgan Stanley Smith Barney LLC Executive Financial Services.

Financial Impact

Proposed sale of ~82,563 shares valued at ~$1.9M, representing approximately 0.38% of C4's $502M market cap.

dilutioninsider ownership

Risk Factors

  • Insider sale may signal lack of confidence or personal liquidity needs; actual sale could pressure stock if executed in size.
  • No specific catalyst identified; sale could be routine portfolio diversification.

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
92% bullish (13 analysts)

Investment Themes

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
144 Filing (Primary)0001950047-26-008190
Document: 0001950047-26-008190-index.html0001950047-26-008190
Document: 0001950047-26-008190.txt0001950047-26-008190

Track record

19 reports on CCCC

Performance horizon

5 of 6 bullish or bearish reports moved the stock their way by T+5. Best: +46.29% at T+60 after the Apr 9, 2026 report. 5 of 6 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $2.71 Now $2.65 −2.03% settles Nov 23
  2. Nov 12, 20264d ago 144 Neutral 2/10 Entry $2.76 Now $2.65 −3.99% settles Nov 20
  3. Nov 6, 202610d ago Institutional Cluster Neutral 2/10 Entry $3.10 to $2.76 Now $2.65 −14.52% ▼ −10.97% −13.56% vs SPY
  4. Nov 5, 202611d ago 8-K Neutral 4/10 No price data
  5. Nov 5, 202611d ago Press Release Neutral 5/10 Entry $2.95 to $2.77 Now $2.65 −10.17% ▼ −6.10% −9.39% vs SPY
  6. Sep 25, 20267w ago 8-K Neutral 4/10 Entry $2.98 to $2.95 Now $2.65 −11.07% ▼ −1.01% −0.79% vs SPY
  7. Sep 25, 20267w ago Press Release Neutral 4/10 Entry $2.98 to $2.95 Now $2.65 −11.07% ▼ −1.01% −0.79% vs SPY
  8. Aug 14, 202613w ago 144 Neutral 3/10 Viewing Entry $4.27 to $4.10 Now $2.65 −37.87% ▼ −3.87% −2.68% vs SPY
  9. Aug 14, 202613w ago Institutional Cluster Bullish 6/10 Entry $4.27 to $4.10 Now $2.65 −37.87% ▼ −3.87% −2.68% vs SPY
  10. Aug 11, 202613w ago 8-K Neutral 5/10 Entry $3.87 to $4.18 Now $2.65 −31.52% ▲ +8.01% +8.41% vs SPY
Showing 10 of 19

US Market Status

Market Closed · Opens in 6h 36m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 14, 2026